Shopping Cart
- Remove All
Your shopping cart is currently empty
DPH
🥰Excellent
Catalog No. T15164Cas No. 484049-04-9
DPH is a potent, cell-permeable activator of c-Abl, demonstrating significant enzymatic and cellular efficacy in stimulating c-Abl activation.
DPH
🥰Excellent
Purity: 99.72%
Catalog No. T15164Cas No. 484049-04-9
DPH is a potent, cell-permeable activator of c-Abl, demonstrating significant enzymatic and cellular efficacy in stimulating c-Abl activation.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $31 | In Stock | |
| 5 mg | $68 | In Stock | |
| 10 mg | $113 | In Stock | |
| 25 mg | $247 | In Stock | |
| 50 mg | $396 | In Stock | |
| 100 mg | $591 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "DPH"
Imatinib
Cited
STI571, ST-1571, CGP057148B
T6230152459-95-5
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.
- $36
Size
QTY
CitedGNF-5
GNF 5
T1803778277-15-9
GNF-5 is a specific non-ATP competitive inhibitor of Bcr-Abl (IC50: 0.22±0.1 uM, Wild-type Abl). It is an analog of GNF-2 with improved pharmacokinetic properties.
- $30
Size
QTY
Dasatinib Cited
BMS-354825
T1448302962-49-8
Dasatinib (BMS-354825) is an orally active, ATP-competitive tyrosine kinase inhibitor that targets Src and Bcr-Abl (Ki=16/30 pM), with antitumor activity, used in the treatment of leukemia and lymphoma.
- $37
Size
QTY
CitedNilotinib monohydrochloride monohydrate
Nilotinib (monohydrochloride monohydrate), AMN107 (monohydrochloride monohydrate)
T2147923288-90-8
Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine kinase inhibitor (TKI), and is active against many BCR-ABL mutants.
- $33
Size
QTY
Masitinib
AB1010
T2609790299-79-5
Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
- $31
Size
QTY
Nilotinib Cited
Tasigna, AMN107
T1524641571-10-0
Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor with oral activity. Nilotinib has antitumor activity and may be used for the treatment of Imatinib-resistant chronic myelogenous leukemia (CML).
- $35
Size
QTY
CitedVodobatinib
K-0706
T88821388803-90-4
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity.
- $31
Size
QTY
Bosutinib hydrate
SKI-606 hydrate, PF-5208763 hydrate, PF-05208763 hydrate
T63875918639-08-4
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia.
- $33
Size
QTY
Pivanex
Pivalyloxymethyl butyrate, AN-9
T16545122110-53-6
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.
- $35
Size
QTY
KW-2449
KW2449
T23411000669-72-6
KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 (IC50: 6.6 nM), modestly effective to Bcr-Abl, FGFR1, and Aurora A; little inhibitory on PDGFRβ, IGF-1R, EGFR.
- $33
Size
QTY
Dasatinib monohydrate Cited
BMS-354825 Monohydrate
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
Size
QTY
CitedSelect Batch
Purity:99.72%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | DPH is a potent, cell-permeable activator of c-Abl, demonstrating significant enzymatic and cellular efficacy in stimulating c-Abl activation. |
| In vitro | DPH represents the first cell-permeable, small-molecule tool compound for c-Abl activation. DPH binds to the myristoyl binding site. It also prevents the formation of the bent conformation of the αI helix through steric hindrance. Which is a mode of action distinct from the previously identified allosteric c-Abl inhibitor, GNF-2, that also binds to the myristoyl binding site [1]. |
| Molecular Weight | 336.32 |
| Formula | C18H13FN4O2 |
| Cas No. | 484049-04-9 |
| Smiles | Fc1ccc(cc1)-c1nn(cc1C1NC(=O)NC1=O)-c1ccccc1 |
| Relative Density. | 1.45 g/cm3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (267.6 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy DPH | purchase DPH | DPH cost | order DPH | DPH chemical structure | DPH in vitro | DPH formula | DPH molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.